Your browser doesn't support javascript.
loading
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.
Garcia-Prieto, Carlos A; Villanueva, Lorea; Bueno-Costa, Alberto; Davalos, Veronica; González-Navarro, Europa Azucena; Juan, Manel; Urbano-Ispizua, Álvaro; Delgado, Julio; Ortiz-Maldonado, Valentín; Del Bufalo, Francesca; Locatelli, Franco; Quintarelli, Concetta; Sinibaldi, Matilde; Soler, Marta; Castro de Moura, Manuel; Ferrer, Gerardo; Urdinguio, Rocio G; Fernandez, Agustin F; Fraga, Mario F; Bar, Diana; Meir, Amilia; Itzhaki, Orit; Besser, Michal J; Avigdor, Abraham; Jacoby, Elad; Esteller, Manel.
Afiliação
  • Garcia-Prieto CA; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Villanueva L; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Bueno-Costa A; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Davalos V; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • González-Navarro EA; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Juan M; Department of Immunology, Hospital Clinic, Barcelona, Spain.
  • Urbano-Ispizua Á; Department of Immunology, Hospital Clinic, Barcelona, Spain.
  • Delgado J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Ortiz-Maldonado V; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Del Bufalo F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Locatelli F; Department of Hematology, University of Barcelona (UB), Barcelona, Spain.
  • Quintarelli C; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Sinibaldi M; Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Madrid, Spain.
  • Soler M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Castro de Moura M; Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Ferrer G; Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Urdinguio RG; Department of Pediatrics, Sapienza University of Rome, Rome, Italy.
  • Fernandez AF; Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Fraga MF; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Bar D; Department of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Meir A; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Itzhaki O; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Besser MJ; Cancer and Leukemia Epigenetics and Biology Program (PEBCL), Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Avigdor A; Nanomaterials and Nanotechnology Research Center (CINNCSIC), Health Research Institute of Asturias (ISPA), Institute of Oncology of Asturias (IUOPA), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Organisms and Systems Biology (BOS), University of Oviedo, Ovi
  • Jacoby E; Nanomaterials and Nanotechnology Research Center (CINNCSIC), Health Research Institute of Asturias (ISPA), Institute of Oncology of Asturias (IUOPA), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Organisms and Systems Biology (BOS), University of Oviedo, Ovi
  • Esteller M; Nanomaterials and Nanotechnology Research Center (CINNCSIC), Health Research Institute of Asturias (ISPA), Institute of Oncology of Asturias (IUOPA), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Organisms and Systems Biology (BOS), University of Oviedo, Ovi
J Natl Cancer Inst ; 114(3): 436-445, 2022 03 08.
Article em En | MEDLINE | ID: mdl-34581788
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article